![]() |
||||||||||||||
|
Researchers report results of studies on atrial fibrillation management Ventricular rate control is more effective in atrial fibrillation (AF) management and valsartan does not reduce AF recurrence, researchers said Tuesday in oral abstract presentations on therapy for AF. Ensuring a stable sinus rhythm was once thought to boost survival in AF and congestive heart failure (CHF). more |
PAID ADVERTISEMENT ![]() |
||||||||||||
Childhood obesity causes subtle changes in heart, arteries Recent studies in children demonstrate that childhood obesity and overweight are not innocuous and that overweight children are beginning to show subtle but important changes in the heart and arteries, researchers noted during a Tuesday news conference. more |
Four Late-Breaking Clinical Trial results presented Exercise training is safe in people with stable heart failure (HF) and is associated with better clinical outcomes even in patients already receiving optimal medical care, suggest results of the randomized, phase III Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing trial. more |
Ablation techniques better than antiarrhythmic drug therapy in treating AF patients The ThermoCool ablation catheter system is superior to continued antiarrhythmic drug (AAD) therapy in atrial fibrillation patients refractory to at least one AAD, according to final outcomes of The ThermoCool AF Trial presented Tuesday. more |
Novel agent for hypertension in development A new class of drug can effectively manage hypertension, according to a study reported Tuesday. PS433540 is the first compound in a novel class of agents called Dual Acting Receptor Antagonists (DARA) that selectively blocks angiotensin (AT1) and endothelin (ETA) receptors. more |
|||||||||||
| © American
Heart Association. Scientific Sessions Daily News is published daily during Scientific Sessions, November 8-12, 2008. |
||||||||||||||